Giorgio Walter Canonica Selected Research

Omalizumab (Xolair)

6/2021	The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations.
6/2021	The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.
1/2021	A Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM).
1/2020	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
1/2020	Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.
1/2020	Plasma Galectin-3 and urine proteomics predict FEV1 improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study.
1/2020	Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.
10/2018	Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
1/2018	Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study.
1/2017	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giorgio Walter Canonica Research Topics

Disease

125	Asthma (Bronchial Asthma) 12/2022 - 04/2002
53	Hypersensitivity (Allergy) 06/2022 - 04/2002
27	Allergic Rhinitis 12/2022 - 07/2005
21	Inflammation (Inflammations) 01/2022 - 02/2005
19	Chronic Obstructive Pulmonary Disease (COPD) 06/2022 - 10/2007
17	Rhinitis 01/2016 - 03/2003
8	Rhinosinusitis 05/2022 - 06/2003
8	Nasal Polyps (Nasal Polyp) 05/2022 - 01/2019
7	Atopic Dermatitis (Atopic Eczema) 05/2022 - 07/2007
7	Chronic Urticaria 06/2021 - 07/2005
5	Anaphylaxis (Anaphylactic Shock) 01/2022 - 04/2002
5	Infections 01/2021 - 02/2009
5	Food Hypersensitivity (Food Allergy) 05/2019 - 08/2005
5	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2019 - 09/2013
5	Urticaria (Hives) 01/2017 - 07/2005
3	Headache (Headaches) 11/2022 - 01/2021
3	Cough 05/2022 - 01/2015
3	Sinusitis 01/2022 - 06/2004
3	Seasonal Allergic Rhinitis (Hay Fever) 01/2019 - 05/2009
2	Chronic Cough 05/2022 - 12/2021
2	Fever (Fevers) 01/2022 - 01/2021
2	Bronchiectasis 01/2021 - 05/2019
2	Eczema 01/2021 - 08/2005
2	COVID-19 05/2020 - 01/2020
2	Airway Remodeling 01/2017 - 11/2014
2	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2015 - 09/2013
2	Bacterial Infections (Bacterial Infection) 01/2015 - 08/2010
2	Conjunctivitis 11/2013 - 03/2012
2	Dermatitis 05/2011 - 08/2005
1	Arthralgia (Joint Pain) 11/2022
1	Noncommunicable Diseases 06/2022
1	Angioedema 06/2022
1	Churg-Strauss Syndrome (Allergic Angiitis) 05/2022
1	Human Influenza (Influenza) 01/2022
1	Hyperplasia 01/2022
1	Metaplasia 01/2022
1	Mastocytosis 01/2022
1	Neurogenic Inflammation 12/2021

Drug/Important Bio-Agent (IBA)

43	AllergensIBA 01/2022 - 01/2003
31	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2022 - 08/2006
28	Biological ProductsIBA 06/2022 - 12/2014
27	Immunoglobulin E (IgE)IBA 01/2022 - 01/2010
20	Omalizumab (Xolair)FDA Link 06/2021 - 07/2007
15	Biomarkers (Surrogate Marker)IBA 05/2022 - 11/2014
12	mepolizumabIBA 11/2022 - 01/2016
11	Pharmaceutical PreparationsIBA 05/2022 - 08/2006
11	CytokinesIBA 01/2022 - 06/2003
9	Monoclonal AntibodiesIBA 10/2021 - 07/2007
8	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2022 - 08/2011
7	benralizumabIBA 02/2022 - 01/2016
7	anti-IgE antibodiesIBA 01/2021 - 11/2014
7	TabletsIBA 01/2019 - 04/2014
6	dupilumabIBA 05/2022 - 01/2016
6	Interleukin-5 (Interleukin 5)IBA 02/2019 - 01/2017
5	VaccinesIBA 05/2022 - 08/2008
5	Interleukin-13IBA 01/2022 - 09/2002
5	Formoterol Fumarate (Oxis)FDA Link 01/2021 - 01/2010
5	Muscarinic AntagonistsIBA 01/2021 - 06/2017
5	Histamine Antagonists (Antihistamines)IBA 01/2015 - 07/2005
4	Bronchodilator Agents (Bronchodilators)IBA 06/2022 - 06/2005
4	Arthropod VenomsIBA 01/2022 - 01/2009
4	Fluticasone (Cutivate)FDA LinkGeneric 12/2020 - 01/2010
4	SteroidsIBA 10/2019 - 08/2006
4	Proteins (Proteins, Gene)FDA Link 01/2017 - 10/2007
3	azelastine (Optivar)FDA LinkGeneric 12/2020 - 04/2014
3	reslizumabIBA 01/2020 - 01/2016
3	Galectin 3 (LGALS3)IBA 01/2020 - 11/2014
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 08/2010
3	rupatadineIBA 01/2019 - 11/2013
3	Environmental Pollutants (Pollutants, Environmental)IBA 01/2018 - 02/2009
3	GlucocorticoidsIBA 01/2016 - 09/2011
3	Broncho-VaxomIBA 08/2015 - 01/2013
3	Bacterial LysatesIBA 08/2015 - 08/2010
3	levocetirizine FDA LinkGeneric 10/2009 - 07/2005
2	COVID-19 VaccinesIBA 05/2022 - 05/2021
2	Interleukin-4 (Interleukin 4)IBA 01/2022 - 01/2016
2	VenomsIBA 01/2022 - 02/2020
2	InterleukinsIBA 01/2022 - 01/2016
2	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 01/2021 - 10/2020
2	Beclomethasone (Beclometasone)FDA Link 01/2021 - 10/2020
2	Tiotropium Bromide (Spiriva)FDA Link 01/2020 - 11/2019
2	PeriostinIBA 01/2017 - 01/2016
2	Budesonide (Pulmicort)FDA LinkGeneric 10/2015 - 01/2009
2	GoldIBA 08/2015 - 10/2007
2	bilastineIBA 01/2015 - 04/2014
2	Histamine (Histamine Dihydrochloride)FDA Link 06/2014 - 07/2005
2	SolutionsIBA 04/2014 - 06/2013
2	LatexIBA 01/2013 - 09/2012
1	Drug CombinationsIBA 12/2022
1	Messenger RNA (mRNA)IBA 05/2022
1	Antitussive Agents (Antitussives)FDA Link 05/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 05/2022
1	Tryptases (Tryptase)IBA 01/2022
1	Ion Channels (Ion Channel)IBA 12/2021

Therapy/Procedure

59	Therapeutics 12/2022 - 10/2003
31	Immunotherapy 12/2022 - 04/2002
10	Precision Medicine 01/2020 - 01/2016
9	Nebulizers and Vaporizers (Inhaler) 01/2021 - 09/2013
8	Drug Therapy (Chemotherapy) 05/2022 - 11/2003
4	Biological Therapy 01/2022 - 05/2020